アービタックスの世界市場レポート 2025年：疫学、パイプライン分析、市場インサイトと予測

アービタックスの市場規模は今後数年で急成長が見込まれます。2029年にはCAGR18％で30億6,850万米ドルに成長します。予測期間における成長の背景には、世界のがん患者数の増加、転移性大腸がんの治療需要の拡大、疾患に対する意識の高まり、新規治療に対する需要の増加、医療従事者の意識の高まりなどがあります。予測期間における主要動向としては、個別化医療の進展、セツキシマブの有効性向上のための継続的研究、バイオシミラーの開発、効果的なマーケティング戦略、医薬品開発の革新などが挙げられます。

世界のがん患者数の増加がアービタックス市場の成長を牽引すると予想されます。がんは、異常な細胞が制御不能に増殖し、身体の他の部位に転移する可能性のある多種多様な疾患を指します。がん患者の世界の増加は、人口の高齢化と、食生活の乱れや運動不足を含む生活習慣リスクの増加が主要原因です。アービタックス（セツキシマブ）は、大腸がんや頭頸部がんなど、EGFRが過剰発現しているがんを治療するためにデザインされた標的治療であり、生存率を改善し、世界のがん負担の管理に役立ちます。例えば、国民保健サービス（NHS）が2024年10月に報告したところによると、2022年に英国で新たにがんと診断された患者数は34万6,217人、1日平均948人で、2021年の32万9,664人から5％増加しました。この増加は男性においてより顕著で、がん診断全体では2021年の16万7,917件から2022年には18万877件へと7％増加しました。したがって、世界のがん罹患率の増加がアービタックス市場を牽引しています。

アービタックス市場の主要動向は、セツキシマブ（アービタックス）の有効性と手頃な価格を改善するための革新的ソリューションの開発に注力していることです。アービタックスの商品名で販売されているセツキシマブは、主に大腸がんや頭頸部がんなど特定のがんの治療に使用されるモノクローナル抗体です。例えば、2023年5月、インドを拠点とする開発・製造受託機関であるEnzene Biosciences Limitedは、転移性大腸がんと頭頸部がんを対象とした抗がん剤アービタックスのバイオシミラーであるセツキシマブを発売しました。これにより、セツキシマブ初のバイオシミラーが承認され、患者にとってより安価な治療選択肢が提供されることになります。セツキシマブは、腫瘍の成長と転移に重要な役割を果たす上皮成長因子受容体（EGFR）を阻害することにより作用します。チャイニーズハムスター卵巣（CHO）細胞株を用いて製造されたEnzeneのバイオシミラー医薬品は、インドやその他の市場における治療の利便性を向上させ、バイオシミラー医薬品のポートフォリオを拡大するという同社の戦略を支援することを目的としています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 バイオ医薬品市場における製品特性

• 分子タイプ
• 投与経路（ROA）
• 作用機序（MOA）
• 安全性と有効性

第4章 市場動向と戦略

第5章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症、景気回復が市場に与える影響を含むマクロ経済シナリオ

第6章 世界の成長分析と戦略分析フレームワーク

• 世界のアービタックス：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のアービタックス市場：成長率分析
• 世界のアービタックス市場の実績：規模と成長、2019～2024年
• 世界のアービタックス市場の予測：規模と成長、2024～2029年、2034年
• 世界のアービタックス：総潜在市場規模（TAM）

第7章 世界市場の価格分析と予測

第8章 市場セグメンテーション

• 世界のアービタックス市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 100mg/50ml注射液
• 200mg/100ml注射液
• 世界のアービタックス市場：製品別、実績と予測、2019～2024年、2024～2029年、2034年
• 錠剤
• 丸薬
• 世界のアービタックス市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 頭頸部がん
• 転移性大腸がん
• 世界のアービタックス市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• その他

第9章 臨床適応症の世界市場疫学

• 薬剤の副作用
• 臨床適応症の発症率と有病率

第10章 地域別・国別分析

• 世界のアービタックス市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のアービタックス市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第11章 アジア太平洋市場

第12章 中国市場

第13章 インド市場

第14章 日本市場

第15章 オーストラリア市場

第16章 韓国市場

第17章 西欧市場

第18章 英国市場

第19章 ドイツ市場

第20章 フランス市場

第21章 東欧市場

第22章 北米市場

第23章 米国市場

第24章 カナダ市場

第25章 南米市場

第26章 中東市場

第27章 アフリカ市場

第28章 競合情勢と企業プロファイル

• アービタックス市場：競合情勢
• アービタックス市場：企業プロファイル
  • Eli Lilly and Co.
  • Bristol Myers Squibb
  • Merck KGaA

第29章 世界市場：パイプライン分析

第30章 世界の市場競合ベンチマーキングとダッシュボード

第31章 主要な合併と買収

第32章 最近の市場動向

第33章 市場の潜在力が高い国、戦略

• アービタックス市場、2029年：新たな機会を提供する国
• アービタックス市場、2029年：新たな機会を提供するセグメント
• アービタックス市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第34章 付録

Erbitux (cetuximab) is a monoclonal antibody used to treat cancers such as metastatic colorectal cancer and head and neck cancer by targeting the epidermal growth factor receptor (EGFR) and inhibiting tumor growth.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main types of erbitux include the 100 mg/50 mL injection and the 200 mg/100 mL injection. The 100 mg/50 mL injection refers to a medical formulation in which 100 milligrams (mg) of the active drug or substance is dissolved in a total volume of 50 milliliters (mL) of liquid. Erbitux products, including tablets and pills, are used for conditions such as head and neck cancer and metastatic colorectal cancer. These products are distributed through various channels, including hospital pharmacies, retail pharmacies, and other outlets.

The erbitux market research report is one of a series of new reports from The Business Research Company that provides erbitux market statistics, including erbitux industry global market size, regional shares, competitors with erbitux market share, detailed erbitux market segments, market trends and opportunities, and any further data you may need to thrive in the erbitux industry. This erbitux market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The erbitux market size is expected to see rapid growth in the next few years. It will grow to $3,068.5 million in 2029 at a compound annual growth rate (CAGR) of 18%. The growth in the forecast period can be attributed to the rising number of cancer cases globally, growing demand for the treatment of metastatic colorectal cancer, increasing awareness of the disease, increasing demand for novel therapeutics, and growing consciousness among medical practitioners. Major trends in the forecast period include advancements in personalized medicine, continuous research to improve cetuximab's efficacy, developments of biosimilars, effective marketing strategies, and innovations in drug development.

The increasing number of cancer cases worldwide is expected to drive the growth of the erbitux market. Cancer refers to a wide variety of diseases where abnormal cells grow uncontrollably and can spread to other parts of the body. The global rise in cancer cases is largely attributed to an aging population and growing lifestyle risks, including poor diet and physical inactivity. Erbitux (cetuximab) is a targeted therapy designed to treat cancers with overexpressed EGFR, such as colorectal and head and neck cancers, improving survival rates and aiding in the management of the global cancer burden. For example, the National Health Service (NHS) reported in October 2024 that in 2022, there were 346,217 new cancer diagnoses in the UK, averaging 948 cases per day, a 5% increase from 2021's 329,664 diagnoses. The rise was more significant among men, with a 7% increase in overall cancer diagnoses, from 167,917 in 2021 to 180,877 in 2022. Therefore, the increasing global incidence of cancer is driving the erbitux market.

A key trend in the erbitux market is the focus on developing innovative solutions to improve the effectiveness and affordability of cetuximab (Erbitux). Cetuximab, marketed under the brand name Erbitux, is a monoclonal antibody used primarily to treat certain cancers, including colorectal and head and neck cancers. For instance, in May 2023, Enzene Biosciences Limited, an India-based contract development and manufacturing organization, launched Cetuximab, a biosimilar of the cancer drug Erbitux, targeting metastatic colorectal and head and neck cancers. This marked the approval of the first biosimilar for cetuximab, offering a more affordable treatment option for patients. Cetuximab works by inhibiting the epidermal growth factor receptor (EGFR), which plays a key role in tumor growth and metastasis. Produced using a Chinese Hamster Ovary (CHO) cell line, Enzene's biosimilar aims to enhance treatment accessibility in India and other markets, supporting the company's strategy to expand its biosimilar portfolio.

In May 2023, Lupin Limited, an India-based pharmaceutical company, formed a partnership with Enzene Biosciences Limited. The collaboration between Lupin and Enzene Biosciences aims to launch the first biosimilar of Cetuximab for treating head and neck cancer in India. This partnership seeks to expand treatment options and improve patient access to therapies for recurrent or metastatic conditions, ultimately enhancing healthcare outcomes for patients dealing with public health challenges related to this type of cancer. Enzene Biosciences Limited is an India-based biotech company that provides Cetuximab, the first biosimilar of the cancer treatment drug Erbitux.

Major players operating in the erbitux market are Eli Lilly and Co.; Bristol Myers Squibb; Merck KGaA

North America was the largest region in the erbitux market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in erbitux report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the erbitux market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The erbitux market consists of sales of products including Vectibix, Tarceva, Iressa, and Tagrisso. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Erbitux Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on erbitux market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for erbitux ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The erbitux market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Types: 100 Mg/50 ML Injection; 200 Mg/100 ML Injection
• 2) By Product: Tablet; Pill
• 3) By Applications: Head And Neck Cancer; Metastatic Colorectal Cancer
• 4) By End User: Hospital Pharmacy; Retail Pharmacies; Other End Users
• Companies Mentioned: Eli Lilly and Co.; Bristol Myers Squibb; Merck KGaA
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Erbitux Market Characteristics

3. Erbitux Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Erbitux Market Trends And Strategies

5. Erbitux Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Erbitux Growth Analysis And Strategic Analysis Framework

• 6.1. Global Erbitux PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Erbitux Market Growth Rate Analysis
• 6.4. Global Erbitux Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 6.5. Global Erbitux Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 6.6. Global Erbitux Total Addressable Market (TAM)

7. Global Erbitux Market Pricing Analysis & Forecasts

8. Erbitux Market Segmentation

• 8.1. Global Erbitux Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 100 Mg/50 ML Injection
• 200 Mg/100 ML Injection
• 8.2. Global Erbitux Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablet
• Pill
• 8.3. Global Erbitux Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Head And Neck Cancer
• Metastatic Colorectal Cancer
• 8.4. Global Erbitux Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacies
• Other End Users

9. Global Erbitux Market Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Erbitux Market Regional And Country Analysis

• 10.1. Global Erbitux Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. Global Erbitux Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Erbitux Market

• 11.1. Asia-Pacific Erbitux Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Erbitux Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Asia-Pacific Erbitux Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Asia-Pacific Erbitux Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Erbitux Market

• 12.1. China Erbitux Market Overview
• 12.2. China Erbitux Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.3. China Erbitux Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.4. China Erbitux Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Erbitux Market

• 13.1. India Erbitux Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. India Erbitux Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. India Erbitux Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Erbitux Market

• 14.1. Japan Erbitux Market Overview
• 14.2. Japan Erbitux Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. Japan Erbitux Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. Japan Erbitux Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Erbitux Market

• 15.1. Australia Erbitux Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.2. Australia Erbitux Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Australia Erbitux Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Erbitux Market

• 16.1. South Korea Erbitux Market Overview
• 16.2. South Korea Erbitux Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. South Korea Erbitux Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.4. South Korea Erbitux Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Erbitux Market

• 17.1. Western Europe Erbitux Market Overview
• 17.2. Western Europe Erbitux Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Western Europe Erbitux Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.4. Western Europe Erbitux Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Erbitux Market

• 18.1. UK Erbitux Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. UK Erbitux Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. UK Erbitux Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Erbitux Market

• 19.1. Germany Erbitux Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Germany Erbitux Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Germany Erbitux Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Erbitux Market

• 20.1. France Erbitux Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. France Erbitux Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. France Erbitux Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Erbitux Market

• 21.1. Eastern Europe Erbitux Market Overview
• 21.2. Eastern Europe Erbitux Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Erbitux Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Erbitux Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Erbitux Market

• 22.1. North America Erbitux Market Overview
• 22.2. North America Erbitux Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. North America Erbitux Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.4. North America Erbitux Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Erbitux Market

• 23.1. USA Erbitux Market Overview
• 23.2. USA Erbitux Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. USA Erbitux Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. USA Erbitux Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Erbitux Market

• 24.1. Canada Erbitux Market Overview
• 24.2. Canada Erbitux Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. Canada Erbitux Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. Canada Erbitux Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Erbitux Market

• 25.1. South America Erbitux Market Overview
• 25.2. South America Erbitux Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. South America Erbitux Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. South America Erbitux Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Erbitux Market

• 26.1. Middle East Erbitux Market Overview
• 26.2. Middle East Erbitux Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. Middle East Erbitux Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. Middle East Erbitux Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Erbitux Market

• 27.1. Africa Erbitux Market Overview
• 27.2. Africa Erbitux Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Africa Erbitux Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.4. Africa Erbitux Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Erbitux Market Competitive Landscape And Company Profiles

• 28.1. Erbitux Market Competitive Landscape
• 28.2. Erbitux Market Company Profiles
  • 28.2.1. Eli Lilly and Co. Overview, Products and Services, Strategy and Financial Analysis
  • 28.2.2. Bristol Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
  • 28.2.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis

29. Global Erbitux Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Erbitux Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Erbitux Market

32. Recent Developments In The Erbitux Market

33. Erbitux Market High Potential Countries, Segments and Strategies

• 33.1 Erbitux Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Erbitux Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Erbitux Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer